Mutational analysis of the GNA11, MMP27, FGD1, TRRAP and GRM3 genes in thyroid cancer

Leenhardt L, Grosclaude P and Chérié-Challine L: Thyroid Cancer Committee: Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid. 14:1056–1060. 2004. View Article : Google Scholar

Sprague BL, Warren Andersen S and Trentham-Dietz A: Thyroid cancer incidence and socioeconomic indicators of health care access. Cancer Causes Control. 19:585–593. 2008. View Article : Google Scholar : PubMed/NCBI

Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI

Liu Z, Hou P, Ji M, et al: Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 93:3106–3116. 2008. View Article : Google Scholar

Van Raamsdonk CD, Griewank KG, Crosby MB, et al: Mutations in GNA11 in uveal melanoma. N Engl J Med. 363:2191–2199. 2010.PubMed/NCBI

Palavalli LH, Prickett TD, Wunderlich JR, et al: Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet. 41:518–520. 2009. View Article : Google Scholar : PubMed/NCBI

Wei X, Walia V, Lin JC, et al: Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet. 43:442–446. 2011. View Article : Google Scholar : PubMed/NCBI

Prickett TD, Wei X, Cardenas-Navia I, et al: Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet. 43:1119–1126. 2011. View Article : Google Scholar : PubMed/NCBI

Hou P, Liu D and Xing M: Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr Relat Cancer. 18:687–697. 2011. View Article : Google Scholar : PubMed/NCBI

Brinckerhoff CE and Matrisian LM: Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol. 3:207–214. 2002. View Article : Google Scholar : PubMed/NCBI

Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI

Freije JM, Balbín M, Pendás AM, Sánchez LM, Puente XS and López-Otín C: Matrix metalloproteinases and tumor progression. Adv Exp Med Biol. 532:91–107. 2003. View Article : Google Scholar : PubMed/NCBI

Orrico A, Galli L, Faivre L, et al: Aarskog-Scott syndrome: clinical update and report of nine novel mutations of the FGD1 gene. Am J Med Genet A. 152A:313–318. 2010. View Article : Google Scholar : PubMed/NCBI

Whitehead IP, Abe K, Gorski JL and Der CJ: CDC42 and FGD1 cause distinct signaling and transforming activities. Mol Cell Biol. 18:4689–4697. 1998.PubMed/NCBI

Murugan AK, Dong J, Xie J and Xing M: MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle. 8:2122–2124. 2009. View Article : Google Scholar : PubMed/NCBI

Murugan AK and Xing M: Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res. 71:4403–4411. 2011. View Article : Google Scholar : PubMed/NCBI

Neff RL, Farrar WB, Kloos RT and Burman KD: Anaplastic thyroid cancer. Endocrinol Metab Clin North Am. 37:525–538. 2008. View Article : Google Scholar

Murugan AK, Dong J, Xie J and Xing M: Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers. Endocr Pathol. 22:97–102. 2011. View Article : Google Scholar : PubMed/NCBI

Mitsiades CS, Kotoula V, Poulaki V, et al: Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab. 91:3662–3666. 2006. View Article : Google Scholar